PRZOOM - /newswire/ -
Waltham, MA, United States, 2008/10/27 - Leading provider of in silico solutions extends integrated “-omics” platform collaboration with FDA’s National Center for Toxicological Research.
Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced a renewed agreement with the National Center for Toxicological Research of the U.S. Food and Drug Administration for the use of Genedata Expressionist® biomarker discovery platform.
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, as well as statistical analysis and interpretation tools, the platform provides a single point of access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Weida Tong, Director of the Center for Toxicoinformatics at the U.S. Food and Drug Administration (FDA), said, “We have successfully applied Genedata Expressionist in a number of FDA projects, including the Critical Path project and the Liver Toxicity Knowledge Base (LTKB) project. Expressionist is an excellent system for monitoring the quality of gene expression data.”
Othmar Pfannes, CEO of Genedata, added, “We are excited about this collaboration with the FDA. Their use of the Genedata Expressionist system for data quality control validates our approach to omics-data analysis.”
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high-throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.